CDTX Quote, Financials, Valuation and Earnings

Cogent Biosciences, Inc. has a net margin of -30201.66% compared to Cidara Therapeutics, Inc.'s net margin of --. Cidara Therapeutics, Inc.'s return on equity of -68.74% beat Cogent Biosciences, Inc.'s return on equity of -104.81%.

Cidara Therapeutics, Inc. has a consensus price target of $221.50, signalling upside risk potential of 0.05%. On the other hand Cogent Biosciences, Inc. has an analysts' consensus of $53.83 which suggests that it could grow by 38.57%. Given that Cogent Biosciences, Inc. has higher upside potential than Cidara Therapeutics, Inc., analysts believe Cogent Biosciences, Inc. is more attractive than Cidara Therapeutics, Inc..

Cidara Therapeutics, Inc. has a beta of 1.561, which suggesting that the stock is 56.074% more volatile than S&P 500. In comparison Cogent Biosciences, Inc. has a beta of 0.468, suggesting its less volatile than the S&P 500 by 53.231%.

Cidara Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cogent Biosciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cidara Therapeutics, Inc. pays -- of its earnings as a dividend. Cogent Biosciences, Inc. pays out -- of its earnings as a dividend.

Cidara Therapeutics, Inc. quarterly revenues are --, which are smaller than Cogent Biosciences, Inc. quarterly revenues of --. Cidara Therapeutics, Inc.'s net income of -$83.2M is higher than Cogent Biosciences, Inc.'s net income of -$102.5M. Notably, Cidara Therapeutics, Inc.'s price-to-earnings ratio is -- while Cogent Biosciences, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cidara Therapeutics, Inc. is 55.23x versus 55.99x for Cogent Biosciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Merck & Co., Inc. has a net margin of -30201.66% compared to Cidara Therapeutics, Inc.'s net margin of 18.15%. Cidara Therapeutics, Inc.'s return on equity of -68.74% beat Merck & Co., Inc.'s return on equity of 36.76%.

Cidara Therapeutics, Inc. has a consensus price target of $221.50, signalling upside risk potential of 0.05%. On the other hand Merck & Co., Inc. has an analysts' consensus of $127.18 which suggests that it could grow by 2.22%. Given that Merck & Co., Inc. has higher upside potential than Cidara Therapeutics, Inc., analysts believe Merck & Co., Inc. is more attractive than Cidara Therapeutics, Inc..

Cidara Therapeutics, Inc. has a beta of 1.561, which suggesting that the stock is 56.074% more volatile than S&P 500. In comparison Merck & Co., Inc. has a beta of 0.269, suggesting its less volatile than the S&P 500 by 73.077%.

Cidara Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & Co., Inc. offers a yield of 2.65% to investors and pays a quarterly dividend of $0.85 per share. Cidara Therapeutics, Inc. pays -- of its earnings as a dividend. Merck & Co., Inc. pays out 45.05% of its earnings as a dividend. Merck & Co., Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Cidara Therapeutics, Inc. quarterly revenues are --, which are smaller than Merck & Co., Inc. quarterly revenues of $16.3B. Cidara Therapeutics, Inc.'s net income of -$83.2M is lower than Merck & Co., Inc.'s net income of $3B. Notably, Cidara Therapeutics, Inc.'s price-to-earnings ratio is -- while Merck & Co., Inc.'s PE ratio is 17.02x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cidara Therapeutics, Inc. is 55.23x versus 4.78x for Merck & Co., Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Olema Pharmaceuticals, Inc. has a net margin of -30201.66% compared to Cidara Therapeutics, Inc.'s net margin of --. Cidara Therapeutics, Inc.'s return on equity of -68.74% beat Olema Pharmaceuticals, Inc.'s return on equity of -45.61%.

Cidara Therapeutics, Inc. has a consensus price target of $221.50, signalling upside risk potential of 0.05%. On the other hand Olema Pharmaceuticals, Inc. has an analysts' consensus of $46.09 which suggests that it could grow by 90.46%. Given that Olema Pharmaceuticals, Inc. has higher upside potential than Cidara Therapeutics, Inc., analysts believe Olema Pharmaceuticals, Inc. is more attractive than Cidara Therapeutics, Inc..

Cidara Therapeutics, Inc. has a beta of 1.561, which suggesting that the stock is 56.074% more volatile than S&P 500. In comparison Olema Pharmaceuticals, Inc. has a beta of 1.926, suggesting its more volatile than the S&P 500 by 92.554%.

Cidara Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Olema Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cidara Therapeutics, Inc. pays -- of its earnings as a dividend. Olema Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Cidara Therapeutics, Inc. quarterly revenues are --, which are smaller than Olema Pharmaceuticals, Inc. quarterly revenues of --. Cidara Therapeutics, Inc.'s net income of -$83.2M is lower than Olema Pharmaceuticals, Inc.'s net income of -$42.2M. Notably, Cidara Therapeutics, Inc.'s price-to-earnings ratio is -- while Olema Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cidara Therapeutics, Inc. is 55.23x versus -- for Olema Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Rhythm Pharmaceuticals, Inc. has a net margin of -30201.66% compared to Cidara Therapeutics, Inc.'s net margin of -82.97%. Cidara Therapeutics, Inc.'s return on equity of -68.74% beat Rhythm Pharmaceuticals, Inc.'s return on equity of -310.34%.

Cidara Therapeutics, Inc. has a consensus price target of $221.50, signalling upside risk potential of 0.05%. On the other hand Rhythm Pharmaceuticals, Inc. has an analysts' consensus of $140.67 which suggests that it could grow by 52.77%. Given that Rhythm Pharmaceuticals, Inc. has higher upside potential than Cidara Therapeutics, Inc., analysts believe Rhythm Pharmaceuticals, Inc. is more attractive than Cidara Therapeutics, Inc..

Cidara Therapeutics, Inc. has a beta of 1.561, which suggesting that the stock is 56.074% more volatile than S&P 500. In comparison Rhythm Pharmaceuticals, Inc. has a beta of 2.058, suggesting its more volatile than the S&P 500 by 105.795%.

Cidara Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Rhythm Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cidara Therapeutics, Inc. pays -- of its earnings as a dividend. Rhythm Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Cidara Therapeutics, Inc. quarterly revenues are --, which are smaller than Rhythm Pharmaceuticals, Inc. quarterly revenues of $57.3M. Cidara Therapeutics, Inc.'s net income of -$83.2M is lower than Rhythm Pharmaceuticals, Inc.'s net income of -$47.5M. Notably, Cidara Therapeutics, Inc.'s price-to-earnings ratio is -- while Rhythm Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cidara Therapeutics, Inc. is 55.23x versus 31.75x for Rhythm Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.